Abstract 4735: Designing a novel 3D co-culture model incorporating patient T-cells to study lipid metabolism as a metabolic vulnerability in KRAS driven non-small cell lung cancer
Flanagan S, Stanley R, Tan SY, Malacrida B, Petit N, O’Reilly D, Naidoo J, Browne S et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 86 (7_Supplement), 4735-4735.  
03-04-2026

3D pentaculture model unveils malignant cell-driven macrophage polarization in high-grade serous ovarian cancer
Malacrida B, Elorbany S, Laforêts F, Karim F, Bryan-Ravenscroft RC, Sideris M, Joy JD, Kotantaki P et al.
Nature Communications, Springer Nature vol. 17 (1) 
25-03-2026

Navitoclax, a Bcl-2/xL inhibitor, and YM155, a survivin inhibitor, in combination with carboplatin, effectively inhibit ovarian cancer tumor growth
Kenny HA, Ip CKM, Kelliher L, Samantaray T, Kordylewicz K, Hoffmann R, Rauch S, Malacrida B et al.
Molecular Cancer Therapeutics, American Association For Cancer Research (Aacr) vol. 24 (8), 1252-1264.  
28-04-2025

Abstract 4160: Lipid metabolism is a metabolic vulnerability in LKB1 mutant, KRAS driven non-small cell lung cancer
Flanagan S, Stanley R, Malacrida B, O’Reilly D, Naidoo J, Murray P, Dowling CM
Cancer Research, American Association For Cancer Research (Aacr) vol. 85 (8_Supplement_1), 4160-4160.  
21-04-2025

Abstract 1677: Navitoclax, a Bcl-2/xL inhibitor, and YM155, a survivin inhibitor, in combination with carboplatin effectively inhibit ovarian cancer tumor growth
Samantaray T, Kenny H, Kelliher L, Lengyel ER, Ip CKM, Kordylewicz K, Hoffmann R, Rauch S et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 85 (8_Supplement_1), 1677-1677.  
21-04-2025

Abstract PR-009: Reconstructing the metastatic tumor microenvironment of high grade serous ovarian cancer using human multicellular in vitro models
Malacrida B, Elorbany S, Maniati E, Bryan-Ravenscroft R, Skingsley SLP, Laforets F, Manchanda R, Balkwill FR
 
04-03-2024

Abstract B079: Human 3D ovarian cancer models reveal malignant cell intrinsic and extrinsic factors that influence CAR-T cell activity
Joy JD, Malacrida B, Laforets F, Kotantaki P, Maniati E, Manchanda R, Hopkins S, Garrobo-Calleja I et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 84 (5_Supplement_2), b079-b079.  
04-03-2024

Abstract B068: FOXM1 mediates the crosstalk between tumor microenvironment and ovarian cancer stem cells as revealed by patient-derived organotypic models
Battistini C, Kenny HA, Nieddu V, Melocchi V, Decio A, Malacrida B, Gatto A, Bianchi F et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 84 (5_Supplement_2), b068-b068.  
04-03-2024

Abstract A016: Organotypic high-throughput screening identifies the combinatorial treatment of navitoclax and YM155 that target chemoresistant ovarian cancer cells
Kenny HA, Ip C, kordylewicz K, Hoffmann R, Rauch S, Malacrida B, Balkwill FR, Battistini C et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 84 (5_Supplement_2), a016-a016.  
04-03-2024

Interferon epsilon and ovarian cancer
Elorbany S, Malacrida B
Trends in Cancer, Elsevier vol. 9 (12), 985-986.  
29-09-2023

Abstract 5957: Chemotherapy-induced extracellular matrix remodeling in HGSOC
Kotantaki P, Laforêts F, Maniati E, Berlato C, Malliouri A, Devlin MJ, Malacrida B, Elorbany S et al.
 
04-04-2023

Abstract 4551: Reconstructing the metastatic tumor microenvironment of high grade serous ovarian cancer: understanding the contribution of malignant cells
Malacrida B, Elorbany S, Maniati E, Laforets F, Manchanda R, Balkwill FR
 
04-04-2023

Abstract 5913: Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatments
Laforets F, Kotantaki P, Malacrida B, Elorbany S, Manchanda R, Donnadieu E, Balkwill F
 
04-04-2023

Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatments
Laforêts F, Kotantaki P, Malacrida B, Elorbany S, Manchanda R, Donnadieu E, Balkwill F
Iscience, Elsevier vol. 26 (4) 
29-03-2023

A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1β
Olivera I, Sanz-Pamplona R, Bolaños E, Rodriguez I, Etxeberria I, Cirella A, Egea J, Garasa S et al.
Cancer Discovery, American Association For Cancer Research (Aacr) vol. 12 (9), 2140-2157.  
30-06-2022

Abstract 693: TGFβ-mediated targeting of the extracellular matrix enhances the migration and cytotoxicity of CAR-T cells in 3D models of ovarian cancer
Joy JD, Malacrida B, Laforêts F, Kotantaki P, Maniati E, Hopkins S, Calleja I, Brett S et al.
Cancer Research, American Association For Cancer Research (Aacr) vol. 82 (12_Supplement), 693-693.  
15-06-2022

Abstract 2642: Using 3-Dimensional in vitro models to unravel the complexity of the metastatic microenvironment in high-grade serous ovarian cancer
Malacrida B, Delaine-Smith R, Nichols S, Maniati E, Jones RL, Knight MM, Pearce OM, Balkwill FR
 
01-07-2021

Expression of Annexin A2 Promotes Cancer Progression in Estrogen Receptor Negative Breast Cancers
Mahdi AF, Malacrida B, Nolan J, McCumiskey ME, Merrigan AB, Lal A, Lowery AJ
Cells, Mdpi vol. 9 (7) 
30-06-2020

Abstract 2027: Understanding the role and regulation of newly synthesized Annexin A2 in the progression of breast cancer
Mahdi AF, Malacrida B, Nolan J, McGourty K, Lowery AJ
Tumor Biology. 
01-07-2019

Purification and characterization of native human elongation factor 2
Flygaard RK, Malacrida B, Kiely P, Jenner LB
Protein Expression and Purification, Elsevier vol. 158, 15-19.  
08-02-2019

ATP synthase F1 subunits recruited to centromeres by CENP-A are required for male meiosis
Collins CM, Malacrida B, Burke C, Kiely PA, Dunleavy EM
Nature Communications, Springer Nature vol. 9 (1) 
13-07-2018

RAB40C regulates RACK1 stability via the ubiquitinproteasome system
Day JP, Whiteley E, Freeley M, Long A, Malacrida B, Kiely P, Baillie GS
Future Science Oa, Taylor & Francis vol. 4 (7) 
02-07-2018

Abstract 1914: Elongation factor 2: A novel target for cancer progression
Malacrida B, Dowling CM, Flygaard RK, Kiely M, Coffey JC, Jenner LB, Kiely PA
 
01-07-2018

Abstract 2100: Using in vitro models to identify newly synthesised proteins involved in the progression of breast cancer
Mahdi AF, Malacrida B, McGourty K, Lowery AJ, Kiely PA
 
01-07-2018

AB071. 60. Using in vitro models to identify and target proteins involved in the progression of breast cancer
Mahdi AF, Malacrida B, Lowery AJ, Kiely PA
Mesentery and Peritoneum, Ame Publishing Company vol. 2 (2), ab071-ab071.  
01-02-2018

Abstract 4485: Identification and characterization of novel RACK1 binding partners that may modulate the elongation phase of protein synthesis
Malacrida B, Flygaard RK, Dowling CM, Coffey JC, Jenner LB, Kiely PA
 
01-07-2017

Studying protein-protein interactions: progress, pitfalls and solutions.
Hayes S, Malacrida B, Kiely M, Kiely PA
Biochemical Society Transactions, Portland Press vol. 44 (4), 994-1004.  
15-08-2016

DHEA modulates the effect of cortisol on RACK1 expression via interference with the splicing of the glucocorticoid receptor
Pinto A, Malacrida B, Oieni J, Serafini MM, Davin A, Galbiati V, Corsini E, Racchi M
British Journal of Pharmacology, Wiley vol. 172 (11), 2918-2927.  
26-03-2015

Matrix structure and microenvironment dynamics correlate with chemotherapy response in ovarian cancer
Laforêts F, Kotantaki P, Elorbany S, Hartlebury J, Joy JD, Malacrida B, Bryan-Ravenscroft RC, Berlato C et al.
In Biorxiv